Journal article
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Abstract
Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having …
Authors
Tan CR; Asoori S; Huang C-Y; Brunaldi L; Popat R; Kastritis E; Martinez-Lopez J; Bansal R; Silva Corraes ADM; Chhabra S
Journal
Blood Cancer Journal, Vol. 15, No. 1,
Publisher
Springer Nature
DOI
10.1038/s41408-025-01259-z
ISSN
2044-5385